אווסטין - Avastin – ויקיתרופות

× ×ª×× × ×¡×

× ×ª×× × ××¡×

×ª××¨×× ××××× ××¡×

15/04/2005

××××××ª ××¡×

×ª×¨××¤× ××××××ª ××¨××©×× ×¢'× ×¨××¤× ××××× ×× ××××× ×××¨×ª

××ª×××× ××¡×

××ª××××	×ª××¨×× ×××××	×ª××× ×§××× ×	Class Effect	××¦× ××××	××¡××¡ ××××××ª

×©××××© ××¡×

××¡××¨×ª ××××× ××¡×

××ª×¨××¤× ×ª×× ×ª× ××××¤×× ×××§×¨×× ××××:
1. ××××× ×¡×¨×× ××¢× ××¡ ××¨××¨×ª×, ××§× ×××¤×× ×¨××©×× ×× ××§× ×××¤×× ××ª×§×× (×©× × ×××××).
  ××××¤×× ××ª××©××¨ ××× ×ª× ××××× ×©××¨× ×××¤× ×-Bevacizumab ××××× ××, ×××¢× ×××××× ×©××××¤×× ×-Bevacizumab ××©×××× ×¢× (Trifluridine + Tipiracil (CD, ××©×¨ ×××¤×× ××©× × ×§××× ×××¤×× ×§××××× ×©×××× ×××××ª×¨×¤×× ××××¡×¡×ª Fluoropyrimidine, Oxaliplatin, Irinotecan, ××¢×× VEGF, ××¢×××¨ ××××× ×©×× RAS wild type ×× ××¢×× EGFR
2. ××××× ×¡×¨×× ×××¢× ×××¡ ×©××× ××ª×¨ ×××××× ××¨××©×× × ××× ×××××××ª ××××¤×× ××××¨× ××§××××ª ×©× ×××××
3. ××× ××ª×¨×¤×× ××××××× ××× ××××¨×× ××¡×× Glioblastoma multiforme ××××¨ ××©× ××××¤×× ×§××× ×-Temozolomide.
  ××ª×§××××ª ×××× ×ª×§××¢ ××¤× ××××× ×/×× ×¢× ×¤× ××× ××××ª ××§××× ×××ª ×©×¤××¨×¡×× ×-JCO:
  Wen PY et al, Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group, Journal of Clinical Oncology 2010 28(11): 1963-1972
4. ×××¤×× ××¡×¨×× ×¨××× ××¡×× Non small cell) NSCLC) ××¡×× ×ª××× ×× ×§×©×§×©×××, ××§× ×××¤××× ×¨××©×× ××¢×××¨ ××××× ××©×× ×××× ××¨××¨×ª× (IV) ×× ××©×× IIIB ×××ª× × ×ª×× (××××× ×¢× ×ª×¤××× ×¤××××¨×× ×××××¨), ××©×××× ×¢× ×××××ª×¨×¤×× ××××¡×¡×ª ×¤×××× ××
5. ×××¤×× ×§× ×¨××©×× ××¡×¨×× ××¤××ª××××× ××ª×§×× ×©× ××©××× (×©×××× IIIb, IIIC, IV ××¤× FIGO), ××××××ª ×××¦××××ª ××¡×××× ×××× ××××¨×ª ××××× - ×©×××× IIIb ×-IIIc ×¢× ×××× ×©××¨××ª ××××¨ × ××ª×× ×× ×©×× IV, ××©×××× ×¢× ×§×¨×××¤×××× ××¤×§×××××§×¡×.
  ××××¤×× ××× ×ª× ×¢× ×××ª×§××××ª ×××× ××××©× ×××¤×× ×©×× ××¢×× ×¢× 12 ××××©× ×××¤××
6. ×××¤×× ×§× ×¨××©×× ××¡×¨×× ××¤××ª××××× ××ª×§×× ×©× ×××¦××¦×¨××ª (×©×××× IIIb, IIIC, IV ××¤× FIGO), ××××××ª ×××¦××××ª ××¡×××× ×××× ××××¨×ª ××××× - ×©×××× IIIb ×-IIIc ×¢× ×××× ×©××¨××ª ××××¨ × ××ª×× ×× ×©×× IV, ××©×××× ×¢× ×§×¨×××¤×××× ××¤×§×××××§×¡×.
  ××××¤×× ××× ×ª× ×¢× ×××ª×§××××ª ×××× ××××©× ×××¤×× ×©×× ××¢×× ×¢× 12 ××××©× ×××¤××
7. ×××¤×× ×§× ×¨××©×× ××¡×¨×× ××¤××ª××××× ×¤×¨×××× ××× ×¨××©×× × ××ª×§×× (×©×××× IIIb, IIIC, IV ××¤× FIGO), ××××××ª ×××¦××××ª ××¡×××× ×××× ××××¨×ª ××××× - ×©×××× IIIb ×-IIIc ×¢× ×××× ×©××¨××ª ××××¨ × ××ª×× ×× ×©×× IV, ××©×××× ×¢× ×§×¨×××¤×××× ××¤×§×××××§×¡×.
  ××××¤×× ××× ×ª× ×¢× ×××ª×§××××ª ×××× ××××©× ×××¤×× ×©×× ××¢×× ×¢× 12 ××××©× ×××¤××
8. ×××¤×× ××©×××× ×¢× ×××××ª×¨×¤×× (paclitaxel or topotecan or pegylated liposomal doxorubicin) ××××× ××××¨×ª (×§× ×©× × ×× ×©×××©×) ×©× ×¡×¨×× ××¤××ª××××× ×©× ××©×××, ×¢××× ××¤×××× ××, ××××××ª ×©××¨× ×§×××× Bevacizumab ×× ××¢×× VEGF ×××¨ ×××××ª×
9. ×××¤×× ××©×××× ×¢× ×××××ª×¨×¤×× (paclitaxel or topotecan or pegylated liposomal doxorubicin) ××××× ××××¨×ª (×§× ×©× × ×× ×©×××©×) ×©× ×¡×¨×× ××¤××ª××××× ×©× ×××¦××¦×¨××ª, ×¢××× ××¤×××× ××, ××××××ª ×©××¨× ×§×××× Bevacizumab ×× ××¢×× VEGF ×××¨ ×××××ª×
10. ×××¤×× ××©×××× ×¢× ×××××ª×¨×¤×× (paclitaxel or topotecan or pegylated liposomal doxorubicin) ××××× ××××¨×ª (×§× ×©× × ×× ×©×××©×) ×©× ×¡×¨×× ××¤××ª××××× ×¤×¨×××× ××× ×¨××©×× ×, ×¢××× ××¤×××× ××, ××××××ª ×©××¨× ×§×××× Bevacizumab ×× ××¢×× VEGF ×××¨ ×××××ª×
11. ×××¤×× ××©×××× ×¢× ×××××ª×¨×¤×× (×ª×¨××××ª ×¤×××× ×× ××©×××× ×¢× Paclitaxel ×× Topotecan ××©×××× ×¢× Paclitaxel) ××××× ×¢××§×©×ª (persistent), ××××¨×ª ×× ××¨××¨×ª××ª ×©× ×§×¨×¦×× ××× ×©× ×¦××××¨ ××¨×× ××××××ª ××××××¨××ª ×××¢×××ª ×¡×××× ××× ×× × ×× ×××× ××¤× Moore criteria, ××××××ª ×©××¨× ×§×××× Bevacizumab ×× ××¢×× VEGF ×××¨ ×××××ª×
××ª× ××ª×¨××¤× ×××××¨× ×××¢×©× ××¤× ××¨×©× ×©× ××××× ×××× ×§××××××, ×¨××¤× ××××× ×××××××××× ×× ×¨××¤× ××××× ×××× ×§×××××× ××××¤× ×××× ×§×××××× ××× ×§××××××ª